Key result
Ascending TEVAR relies largely on off-label devices, with only one dedicated graft in pivotal trials.
Why the study?
Many patients with ascending aortic disease are unsuitable for open surgical repair, yet the absence of dedicated endovascular devices leaves clinicians reliant on improvised and off-label solutions amid a growing mismatch between clinical demand and available technology.
Highlights the growing gap between clinical demand for ascending TEVAR in surgical-ineligible patients and the severe lack of dedicated, biomechanically compatible endovascular devices.
Answers are grounded in this paper and cite their sources.
Clinicians face ongoing reliance on off-label devices for ascending repair; leaves open the need for dedicated device trials and prospective registries.
Open surgical repair remains the gold standard for ascending aortic disease, yet many patients are unsuitable for surgery, and the absence of dedicated endovascular devices has left clinicians reliant on improvised and off-label solutions. This narrative review traces the evolution of devices and techniques used in ascending thoracic endovascular aortic repair (aTEVAR), the anatomic and biomechanical challenges unique to the ascending segment, and the growing mismatch between clinical demand and available technology. aTEVAR has been performed with increasing frequency over two decades, predominantly using off-label, physician-modified, and custom-made devices. The only dedicated device to reach clinical use, the Cook Zenith Ascend, has been discontinued, leaving the Gore Ascending Stent-graft as the sole device in active pivotal investigation. Ex vivo and computational studies suggest a clinically relevant compliance mismatch between native ascending tissue and current stent-graft materials. The field may be approaching an inflection point: clinical use is growing and a consensus framework now exists, yet the device landscape remains underdeveloped. Accelerated investment in dedicated device development, prospective registries, and biomechanically informed design appears urgently required.
No takes yet. Share an insight, caveat, or question.
Kort et al. (2026) conducted a review in Ascending aortic disease. Ascending thoracic endovascular aortic repair (aTEVAR) vs. Open surgical repair was evaluated. Ascending thoracic endovascular aortic repair relies predominantly on off-label devices, with only the Gore Ascending Stent-graft currently in active pivotal investigation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: